var args = "PaperID=" + item + "&RefererUrl=" + refererrurl + "&DownloadUrl="+downloadurl; // url = url + "?" + args + "&rand=" + RndNum(4); // //// window.setTimeout("show('" + url + "')", 500); // } // function pdfdownloadjudge() { // $("a").each(function(index) { // var rel = $(this).attr("rel"); // if (rel == "true") { // $(this).removeAttr("onclick"); // $(this).attr("href","#"); // //$(this).bind('click', function() { SetNumTwo(30308)}); // var url = "../userInformation/PDFLogin.aspx"; // var refererrurl = document.referrer; // var downloadurl = window.location.href; // var args = "PaperID=" + 30308 + "&RefererUrl=" + refererrurl + "&DownloadUrl=" + downloadurl; // url = url + "?" + args + "&rand=" + RndNum(4); // // $(this).bind('click', function() { ShowTwo(url)}); // } // }); // } // //获取下载pdf注册的cookie // function getcookie() { // var cookieName = "pdfddcookie"; // var cookieValue = null; //返回cookie的value值 // if (document.cookie != null && document.cookie != '') { // var cookies = document.cookie.split(';'); //将获得的所有cookie切割成数组 // for (var i = 0; i < cookies.length; i++) { // var cookie = cookies[i]; //得到某下标的cookies数组 // if (cookie.substring(0, cookieName.length + 2).trim() == cookieName.trim() + "=") {//如果存在该cookie的话就将cookie的值拿出来 // cookieValue = cookie.substring(cookieName.length + 2, cookie.length); // break // } // } // } // if (cookieValue != "" && cookieValue != null) {//如果存在指定的cookie值 // return false; // } // else { // // return true; // } // } // function ShowTwo(webUrl){ // alert("22"); // $.funkyUI({url:webUrl,css:{width:"600",height:"500"}}); // } //window.onload = pdfdownloadjudge;
NS> Vol.5 No.4, April 2013
Share This Article:
Cite This Paper >>

Radioiodination and biological evaluation of valsartan as a tracer for cardiovascular disorder detection

Abstract Full-Text HTML Download Download as PDF (Size:598KB) PP. 526-531
DOI: 10.4236/ns.2013.54066    2,944 Downloads   4,513 Views   Citations
Author(s)    Leave a comment
A. M. Amin, A. Abd El-bary, A. Abd El-Mohty, Shokry M. Saad, D. M. El-Sharawy

Affiliation(s)

Cyclotron Project, Nuclear Research Centre Atomic Energy Authority, Cairo, Egypt.
Labelled Compound Department, Hot Lab Center, Atomic Energy Authority, Cairo, Egypt.
Nuclear Research Center, Atomic Energy Authority, Cairo, Egypt.
Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Radioactive Isotopes and Generators Department, Atomic Energy Authority, Cairo, Egypt.

ABSTRACT

A procedure for radioiodination of valsartan with iodine-125 is carried out via an electrophilic substitution of hydrogen atom with the iodonium cation I+. All reaction parameters were studied to optimize the labeling conditions of valsartan and to obtain a maximum radiochemical yield (RCY) of the 125I-Valsartan [125I-Val]. By using 3.7 MBq of Na125I, 50 μg of valsartan (0.2 mM) as substrate, 25 μg of Iodogen (0.15 mM) as oxidizing agent in ethanol at room temperature for 30 min, the radiochemical yield of 125I-Val was 98.6% The radiochemical yield was determined by electrophoresis using cellulose acetate moistened with 0.02 M phosphate buffer pH 7. The labeled compound was separated and purified by means of high-pressure liquid chromatography (HPLC). The biological distribution in normal mice indicates the suitability of radioiodinated valsartan to image any cardiovascular disorders.

KEYWORDS

Valsartan; Radioiodination; Cardiovascular Disorder Imaging

Cite this paper

Amin, A. , El-bary, A. , El-Mohty, A. , Saad, S. and El-Sharawy, D. (2013) Radioiodination and biological evaluation of valsartan as a tracer for cardiovascular disorder detection. Natural Science, 5, 526-531. doi: 10.4236/ns.2013.54066.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Hiari, N. and Rudd, J.H.F. (2011) FDG-PET imaging and cardiovascular inflammation. Current Cardiology Reports, 13, 43-48.
[2] Rogers, I.S. and Tawakol, A. (2011) Imaging of coronary inflammation with FDG-PET: Feasibility and clinical hurdles. Current Cardiology Reports.
[3] Matsunari, I., Taki, J., Nakajima, K., Tonami, N. and Hisada, K. (2003) Myocardial viability assessment using nuclear imaging. Annals of Nuclear Medicine, 17, 169 179.
[4] Barakat, K., Clark, R. and Davi, M. (2004) Valsartan hypertension and cardiovascular disease book. CSF Medical Communications, Witney.
[5] Aronson, J.K. (2009) Meyler’s side effects of cardiovascular drugs book. Elsevier Science, Amsterdam.
[6] Holwerda, N.J., Fogari, R., Angeli, P., Porcellati, C., Hereng, C. and Oddou-Stock, P. (1996) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. Journal of Hypertension, 14, 1147-1151. doi:10.1097/00004872-199609000-00016
[7] Black, H.R., Graff, A., Shute, D., Stoltz, R., Ruff, D. and Levine, J. (1997) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Journal of Human Hypertension, 11, 483-489. doi:10.1038/sj.jhh.1000482
[8] Waldmeier, F., Flesch, G., Müller, P., Winkler, T., Kriemler, H.P., Bühlmayer, P. and De Gasparo, M. (1997) Phar macokinetics, disposition and biotransformation of [14C] radiolabeled valsartan in healthy male volunteers after a single oral dose. Xenobiotica, 27, 59-71.
[9] Hermanson, G.T. (2008) Bioconjugated techniques book. 2nd Edition, Elsevier, Amsterdam.
[10] El-Azony, K.M., El-Mohty, A.A., Killa, H.M., Seddik, U. and Khater, S.I. (2008) An investigation of the 125I-radio iodination of colchicine for medical purposes. Journal of Labelled Compounds and Radiopharmaceuticals, 52, 1. doi:10.1002/jlcr.1556
[11] Attallah, K.M. (2002) Pharmaceutical formulation, radio chemical and biological evaluation of some iodine-125 labeled cytotoxic compounds as possible radiotherapeutic agents. M.Sc. Thesis, Zagazig University.
[12] Rhodes, B.A. (1974) Technetium-99m labeled polypeptides for imaging. Seminars in Nuclear Medicine, 4, 281. doi:10.1016/S0001-2998(74)80015-2
[13] Knust, E.J., Dutschka, K. and Machulla, H.J. (1990) Ra diopharmaceutical preparation of 3-123I-α-methyltyrosine for nuclearmedical applications. Journal of Radioanalytical and Nuclear Chemistry, 10, 144
[14] EL-Ghany, E.A., Moustafa, D. and Shokry, M.S. (2009) Iodine-125-Tamoxifan (125ITX); radioligand for visualization of estrogen receptors: Preparation and tissue distribu tion. Arab Journal of Nuclear Sciences and Applications, 42, 80.
[15] El-Azony, K.M. (2010) Preparation of 125I-celecoxib with high purity as a possible tumor agent. Journal of Radioanalytical and Nuclear Chemistry, 285, 315-320.

  
comments powered by Disqus
NS Subscription
E-Mail Alert
NS Most popular papers
Publication Ethics & OA Statement
NS News
Frequently Asked Questions
Recommend to Peers
Recommend to Library
Contact Us

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.